Tamaz Shaburishvili

Spironolactone for Heart Failure with Preserved Ejection Fraction

Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Medicine, Cardiology, Pharmacology +16

Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

Marc A. Pfeffer, Brian Claggett, Susan F. Assmann et al. · Circulation · 2014 · 1K citations

Medicine, Cardiology, Pharmacotherapy +15

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · The Lancet · 2020 · 761 citations · Full text

Medicine, Cardiology, Iron Metabolism Disorders +11

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 331 citations

Medicine, Cardiology, Pharmacology +14

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

Akshay S. Desai, Eldrin F. Lewis, Rebecca Li et al. · American Heart Journal · 2011 · 275 citations

Medicine, Cardiology, Pharmacology +15